Kymera
dependency seen across a large subset of tumor types large franchise potential in liquid and solid tumors | Kymera
Company
Deck Type
Sector
Industry
Deck date
December 2021
Slide
82 of 105
Related slides by other companies
Alkermes
Investor Day
March 2021
demonstrated anti tumor activity in melanoma and renal cell carcinoma dose tumor type prior therapy lines best overall response decrease in target lesions time on therapy weeks continuing therapy mucosal melanoma mucosal melanoma unconfirmed cutaneous melanoma melanoma vaccine renal cell carcinoma renal cell carcinoma placebo awaiting confirmation awaiting confirmation awaiting confirmation yes no yes yes yes data cutoff march reported after data extraction partial response recommended phase dose | Alkermes
BioAtla
Investor Presentation
August 2022
promising preclinical results with cab cab antibody | BioAtla
Omnicell
Investor Presentation
August 2023
backlog million backlog | Omnicell
Boundless Bio
IPO
March 2024
enable cancer cells to resist therapies by rapidly adapting dependency a rode | Boundless Bio
Other recent decks by Kymera
See all presentations (7 decks)
Investor Presentation
December 2023
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
June 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io